0001437749-20-013254.txt : 20200616 0001437749-20-013254.hdr.sgml : 20200616 20200616170903 ACCESSION NUMBER: 0001437749-20-013254 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20200615 FILED AS OF DATE: 20200616 DATE AS OF CHANGE: 20200616 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Tardugno Michael H CENTRAL INDEX KEY: 0001384550 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-15911 FILM NUMBER: 20967207 MAIL ADDRESS: STREET 1: 10220-L OLD COLUMBIA ROAD CITY: COLUMBIA STATE: MD ZIP: 21046-2364 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Celsion CORP CENTRAL INDEX KEY: 0000749647 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 521256615 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 997 LENOX DRIVE STREET 2: SUITE 100 CITY: LAWRENCEVILLE STATE: NJ ZIP: 08648 BUSINESS PHONE: (609) 896-9100 MAIL ADDRESS: STREET 1: 997 LENOX DRIVE STREET 2: SUITE 100 CITY: LAWRENCEVILLE STATE: NJ ZIP: 08648 FORMER COMPANY: FORMER CONFORMED NAME: CELSION CORP DATE OF NAME CHANGE: 19980515 FORMER COMPANY: FORMER CONFORMED NAME: CHEUNG LABORATORIES INC DATE OF NAME CHANGE: 19920703 4 1 rdgdoc.xml FORM 4 X0306 4 2020-06-15 0000749647 Celsion CORP CLSN 0001384550 Tardugno Michael H C/O CELSION CORPORATION 997 LENOX DRIVE, SUITE 100 LAWRENCEVILLE NJ 08648 1 1 Chairman, President and CEO Option to Purchase Celsion Corporation Common Stock 3.66 2020-06-15 4 A 0 135000 0 A 2021-06-15 2030-06-15 Celsion Corporation Common Stock 135000 1346071 D Option to Purchase Celsion Corporation Common Stock 2.22 2020-06-15 4 D 0 850000 0 D 2018-05-15 2028-05-15 Celsion Corporation Common Stock 850000 510071 D Option to Purchase Celsion Corporation Common Stock 2.58 2020-06-15 4 A 0 850000 0 A 2018-05-15 2028-05-15 Celsion Corporation Common Stock 850000 1346071 D Represents the closing price of Celsion Corporation Common Stock on the date of grant. The options vest as follows: 1/3 on the one year anniversary of the date of grant; 1/3 on the second year anniversary of the date of grant; and 1/3 on the third year anniversary of the date of grant. The transaction reported herein reflects a one-time stock option repricing that became effective on June 15, 2020 and is being reported in this manner solely to comply with the technical reporting requirements under Section 16(a) of the Securities Exchange Act of 1934. Pursuant to the settlement agreement as filed as Exhibit 10.2 on Form 8K dated June 16, 2020, the per share exercise price of the Employee Stock Option (right to buy) has been amended to increase such per share exercise price from $2.22 to $2.58. There have been no other changes to the terms of the Employee Stock Option (right to buy). /s/ Timothy J Tumminello, Controller and CAO 2020-06-16